| 148 |
Exenatide for type 2 diabetes mellitus |
WITHDRAWN - Policy no longer required:Â local prescribing guidance (Traffic Lights) applies |
| 128 |
Sorafenib for advanced hepatocellular cancer |
WITHDRAWN - Policy no longer required: NICE TA189 applies (and does not recommend use of sorafenib for advanced hepatocellular cancer) |
| 123 |
Lenalidomide for multiple myeloma |
WITHDRAWN
Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
TA171 June 2009
NICE recommends lenalidomide in combination with dexamethasone, within its licensed indication, as an option for the treatment of multiple myeloma only in people who have received two or more prior therapies. For people who remain on treatment for more than 26 cycles (normally a period of 2 years) the drug cost will be met by the manufacturer.
Clinicians and patients should view the full policy at the NICE website: http://guidance.nice.org.uk/TA171
|
| 111 |
Suniinib for first or second line of treatment for metastatic/advanced renal cell cancer |
WITHDRAWN
Sunitinib for renal cell carcinoma
TA169 March 2009
NICE recommends sunitinib as a first-line treatment option for people with advanced and/or metastatic renal cell carcinoma who are suitable for immunotherapy and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Clinicians and patients should view the full policy at the NICE website: http://guidance.nice.org.uk/TA169
|
| 110 |
Abdominal aortic aneurysms - endovascular repair |
WITHDRAWN
Abdominal aortic aneurysms – endovascular stent grafts
TA 167 January 2001
NICE recommends endovascular stent-grafts as a possible treatment for people with abdominal aortic aneurysms if the aneurysm is below their kidney and has not burst, surgery is appropriate, and the patient has given informed consent.
Clinicians and patients should view the full policy at the NICE website: http://guidance.nice.org.uk/TA167/Guidance/pdf/English |
| 95 |
Use of Imatinib for Chronic Myeloid Leukaemia |
WITHDRAWN
Imatinib for chronic myeloid leukaemia
TA70 October 2003
NICE recommends imatinib as first-line treatment for people with Philadelphia-chromosome-positive chronic myeloid leukaemia (CML) in the chronic phase.
Imatinib is recommended as an option for the treatment of people with Philadelphia-chromosome-positive CML who initially present in the accelerated phase or with blast crisis. Additionally, imatinib is recommended as an option for people who present in the chronic phase and then progress to the accelerated phase or blast crisis if they have not received imatinib previously.
Clinicians and patients should view the full policy at the NICE website: http://guidance.nice.org.uk/TA70 |
| 93 |
28 day prescribing |
WITHDRAWN |
| 90 |
Omalizumab for severe persistent allergic asthma |
WITHDRAWN
Omalizumab for severe persistent allergic asthma
TA133 November 2007
NICE recommends omalizumab, within its licensed indication, as an option for the treatment of severe persistent allergic (IgE mediated) asthma as add-on therapy to optimised standard therapy, only in adults and adolescents (12 years and older) who have been identified as having severe unstable disease.
Clinicians and patients should view the full policy at the NICE website: http://guidance.nice.org.uk/TA133
|
| 89 |
Erlotinib for the treatment of non-small-cell lung |
WITHDRAWN
Erlotinib for the treatment of non-small-cell lung cancer
TA162 November 2008
NICE recommends erlotinib, within its licensed indication, as an alternative to docetaxel as a second-line treatment option for patients with non-small-cell lung cancer (NSCLC) only on the basis that it is provided by the manufacturer at an overall treatment cost (including administration, adverse events and monitoring costs) equal to that of docetaxel. Erlotinib is not recommended for the second-line treatment of locally advanced or metastatic NSCLC in patients for whom docetaxel is unsuitable, or for third-line treatment after docetaxel therapy.
Clinicians and patients should view the full policy at the NICE website: http://guidance.nice.org.uk/TA162
|
| 86 |
Docetaxel in Hormone Refractory Metastatic
Prostate Cancer |
WITHDRAWN
Docetaxal for the treatment of hormone refractory metastatic prostate cancer
TA101 June 2006
NICE recommends docetaxel (up to 10 cycles), within its licensed indications, as a treatment option for men with hormone-refractory metastatic prostate cancer only if their Karnofsky performance-status score is 60% or more.
Clinicians and patients should view the full policy at the NICE website: http://guidance.nice.org.uk/TA101 |
| 85 |
Inhaled insulin |
WITHDRAWN
Product no longer manufactured |
| 79 |
The use of trastuzumab (Herceptin) for early breast cancer
|
WITHDRAWN
Early and locally advanced breast cancer
February 2009 TA107 incorporated into Clinical Guideline No.80
NICE recommends that trastuzumab is provided to appropriate women at 3-week intervals for 1 year or until disease recurrence as an adjuvant treatment to women with HER2-positive early invasive breast cancer following surgery, chemotherapy, and radiotherapy when applicable.
Clinicians and patients should view the full guidance at the NICE website: http://guidance.nice.org.uk/CG80 |
| 78 |
Pemetrexed disodium for the treatment of malignant pleural mesothelioma |
WITHDRAWN
Pemetrexed for the treatment of malignant pleural mesothelioma
TA135 January 2008
NICE recommends pemetrexed as a treatment option for malignant pleural mesothelioma only in people who have a World Health Organization performance status of 0 or 1, who are considered to have advanced disease and for whom surgical resection is considered inappropriate.
Clinicians and patients should view the full policy at the NICE website: http://guidance.nice.org.uk/TA135
|
74
|
Cinacalcet for the treatment of uncontrollable secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis treatment |
WITHDRAWN
Cinacalcet for the treatment of secondary hyperparathyroidism inpatients with end-state renal disease on maintenance dialysis treatment
TA 117 January 2007
NICE does not recommend cinacalcet for the routine treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy. NICE does recommend cinacalcet for the treatment of refractory secondary hyperparathyroidism in patients with end-stage renal disease (including those with calciphylaxis) in selected patients.
Clinicians and patients should view the full policy at the NICE website: http://guidance.nice.org.uk/TA117
|
| 73 |
Rimonabant for the treatment of overweight and obese adults |
The European Medicines Agency (EMEA) has suspended the marketing authorisation for rimonabant across the EU. As a result of the EMEA's decision, NICE has temporarily withdrawn its Technology Appraisal Guidance (TA144) on the use of rimonabant for the treatment of overweight and obese patients. Accordingly, policy 73 has been withdrawn until further notice. A copy of the Department of Health's safety alert (CAS) can be viewed here - download the Rimonabant CAS message (43 KB) and additional information and guidance for clinicians is available from the EMEA website. |
| 65 |
Reimbursement
for Live Organ Donors |
WITHDRAWN |
| 63 |
Imatinib
for the treatment of unresectable and/or metastatic gastro-intestinal
stromal tumours (GIST) |
WITHDRAWN
Imatinib for the treatment of GIST
TA 86 October 2004
NICE recommends Imatinib treatment at 400 mg/day as first-line management of people with KIT (CD117)-positive unresectable and/or KIT (CD117)-positive
metastatic gastro-intestinal stromal tumours.
Clinicians and patients should view the full policy at the NICE website: http://guidance.nice.org.uk/TA86 |
| 60 |
Laronidaose (Aldurazyme) for Mucopolysaccharidosis type 1 (MPS 1) |
WITHDRAWN |
| 54 |
Bosentan for use
in patients with pulmonary arterial hypertension |
WITHDRAWN This policy statement is now encompassed in PS 149 Drug therapies for pulmonary hypertension. |
| 52 |
The use of Continuous Subcutaneous insulin infusion for diabetes - Insulin Pumps |
WITHDRAWN
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus
TA151 July 2008
NICE recommends continuous subcutaneous insulin infusion (CSII or 'insulin pump') therapy as a treatment option for adults and children 12 years and older with type 1 diabetes mellitus who meet defined treatment criteria.
Clinicians and patients should view the full policy at the NICE website: http://guidance.nice.org.uk/TA151 |
| 50 |
Activated protein C (drotrecogin alfa) for severe sepsis and multiple organ failure (103KB) |
Eli Lilly and Company announces withdrawal of  Xigris(R) [drotrecogin alfa (activated)] in all markets following results of the PROWESS-SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock.
Following the withdrawal of the drug on grounds of clinical effectiveness, Policy Statement No. 50 is WITHDRAWN. Clinicians with additional questions about Xigris (Activated protein C - drotrecogin alfa) should visit www.Lilly.com. |
| 47 |
Zanamivir, oseltamivir and amantadine for the treatment of influenza |
WITHDRAWN - Policy no longer required: NICE Technology Appraisal Guidance (TA158 and TA168) apply |
| 46 |
Oseltamivir and amantadine for the prevention of influenza |
WITHDRAWN - Policy no longer required: NICE Technology Appraisal Guidance (TA158 and TA168) apply |
| 44 |
The use of Cholinesterase
inhibitors in people with a learning disability |
Cholinesterase inhibitors may be used in people with
learning disability provided the patient's progress is observed.
WITHDRAWN - REPLACED BY NUMBER 17b |
| 40 |
Gamolenic acid for inflammation and autoimmune disease |
WITHDRAWN - Policy no longer required:Â local prescribing guidance (Traffic Lights) applies |
| 39 |
Nicotine replacement therapy and bupropion for smoking cessation |
WITHDRAWN - Policy no longer required: NICE Public Health Guidance (PH10) and Technology Appraisal Guidance (TA123) apply |
| 38 |
Sibutramine |
WITHDRAWN 22 JANUARY 2010.
Following the publication of new safety information, the European Medicines Agency (EMA) has reviewed the prescribing status of sibutramine (Reductil) and has found that the cardiovascular risks of sibutramine outweigh its benefits. Therefore, the EMA has recommended the suspension of the marketing authorisation for sibutramine across the European Union. Accordingly, until further notice, SIBUTRAMINE SHOULD NOT BE PRESCRIBED and the following actions are recommended.
- Doctors should not issue any new prescriptions for sibutramine, and should review the treatment of those who are currently taking this medicine
- Pharmacists should not dispense any prescriptions for sibutramine and should advise patients to make an appointment to see their doctor at the next convenient time
- Patients who are currently being treated with sibutramine should be advised to schedule an appointment at the next convenient time with their doctor to discuss alternative measures to lose weight, including use of diet and exercise regimes. Patients may stop treatment before their appointment if they wish.
The MHRA's statement on this issue can be read in full here: Sibutramine CAS Jan 2010 (67 KB) |
| 37 |
Nicotine Replacement Therapy on FP10 |
WITHDRAWN - REPLACED BY NUMBER 39 |
| 35 |
Bupropion (Zyban) |
WITHDRAWN
- REPLACED BY NUMBER 39 |
| 33 |
Removal of wisdom
teeth (third molars) guidance from NICE |
WITHDRAWN
Removal of wisdom teeth
TA1 March 2000
NICE recommends that the practice of prophylactic removal of pathology-free impacted third molars should be discontinued in the NHS.
Clinicians and patients should view the full policy at the NICE website: http://guidance.nice.org.uk/TA1 |
| 32 |
Antipsychotic (neuroleptic) medication for elderly patients with dementia |
WITHDRAWN - Policy no longer required: NICE TA217 covers the use of AChEIs in behavioural difficulties. |
| 29 |
Zanamivir (Relenza) |
WITHDRAWN - REPLACED
BY NUMBERS 46 AND 47 |
| 28 |
Orlistat for obesity |
WITHDRAWN -
Recommendations in NICE Clinical Guideline No. 43 Obesity apply. |
| 26 |
BCG Immunisation |
WITHDRAWN |
| 24 |
Appeals process
against refusal of individual patient purchasing requests |
WITHDRAWN
Oxfordshire PCT's Appeals Process has been updated and is now incorporated in the Individual Patients' Requests (IPR) policy. |
| 20 |
Purchase of procedures that are not explicitly
included or excluded from fundholding |
WITHDRAWN |
| 17 |
Acetylcholinesterase Inhibitors (donepezil, rivastigmine and galantamine) and memantine) in Alzheimer’s disease |
WITHDRAWN
Alzheimer’s disease - donepezil, galantamine, rivastigmine and memantine
TA 217 March 2011
NICE recommends:
- donepezil, galantamine and rivastigmine as options for managing mild as well as moderate Alzheimer’s disease,
- memantine as an option for managing moderate Alzheimer’s disease for people who cannot take AChE inhibitors, and as an option for managing severe Alzheimer’s disease.
Clinicians and patients should view the full policy at the NICE website http://guidance.nice.org.uk/TA217/Guidance/pdf/English |
| |
Low Alpha foeto-protein
levels and Down's Syndrome and Nuchal Fold Screening |
WITHDRAWN |
| 12 |
Proton pump inhibitors |
WITHDRAWN
Policy out of date; no longer required as covered by local prescribing guidance (Traffic Lights) |
| 9 |
Riluzole for Motor
Neurone Disease |
WITHDRAWN
Riluzole for Motor Neurone Disease
TA 20 January 2001
NICE recommends the use of Riluzole for the treatment of individuals with the amyotrophic lateral sclerosis form of Motor Neurone Disease (MND).
Clinicians and patients should view the full policy at the NICE website: http://guidance.nice.org.uk/TA20 |
| 7 |
Mammography screening
for women aged < 50 yrs |
WITHDRAWN |
| 4 |
Follow up Outpatient
appointments out of area |
WITHDRAWN |
| 3 |
Operative Podiatry |
WITHDRAWN |